RJFSA
LJPC

Raymond James Financial Services Advisors’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Raymond James Financial Services Advisors’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-15,700
Closed -$66K – 2957
2020
Q1 		$66K Buy
15,700
+200
+1% +$1.26K ﹤0.01% 2286
2019
Q4 		$61K Buy
+15,500
New +$91.5K ﹤0.01% 2751

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Raymond James Financial Services Advisors's LJPC Position: Q2 2020 in Review

Raymond James Financial Services Advisors sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2020, closing a stake of 15,700 shares — an estimated $66K sold.

Raymond James Financial Services Advisors first reported a position in LJPC in Q4 2019 and held it in 2 quarters. The position peaked at $66K in Q1 2020. 76 funds tracked by Wall St. Rank hold LJPC as of Q2 2020.

  • Raymond James Financial Services Advisors reported no remaining La Jolla Pharmaceutical Company position as of Q2 2020 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 15,700 La Jolla Pharmaceutical Company shares in Q2 2020, an estimated $66K.
  • Raymond James Financial Services Advisors first reported a position in La Jolla Pharmaceutical Company in Q4 2019 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's La Jolla Pharmaceutical Company position peaked at $66K in Q1 2020.
  • 76 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2020, filed 17 Jul 2020.